CeriBell, Inc. (NASDAQ:CBLL) Q4 2024 Earnings Conference Call February 25, 2025 4:30 PM ET Company Participants Brian Johnston - Gilmartin Group Xingjuan Chao - President and Chief Executive Officer Scott Blumberg - Chief Financial Officer Conference Call Participants Stephanie Piazzola - Bank of America Robert Marcus - JPMorgan Chase & Co. Macauley Kilbane - William Blair & Company Joshua Jennings - TD Cowen William Plovanic - Canaccord Genuity Corp. Operator Operator Hello, and thank you for standing by. ...

Financial Data and Key Metrics Changes - Revenue for Q4 2024 was $18.5 million, reflecting a 41% increase from $13.1 million in Q4 2023 [31] - Full-year revenue totaled $65.4 million, representing a 45% growth over 2023 [33] - Gross margin for Q4 2024 was 88%, compared to 85% in the prior year [34] - Net loss for Q4 2024 was $12.6 million, or a loss of $0.40 per share, compared to a loss of $8.3 million, or a loss of $1.53 per share in Q4 2023 [36] Business Line Data and Key Metrics Changes - Product revenue for Q4 2024 was $14.1 million, a 41% increase from $10.0 million in Q4 2023 [32] - Subscription revenue for Q4 2024 was $4.4 million, representing a 40% increase from $3.1 million in Q4 2023 [32] - Active accounts increased to 529 as of December 31, 2024, an increase of 25 during the quarter [16] Market Data and Key Metrics Changes - The company estimates there are 6,000 acute care facilities in the U.S. that could benefit from its offerings [17] - The current market for seizure detection and management in the acute care setting is valued at $2 billion in the U.S. [29] Company Strategy and Development Direction - The company plans to expand its account acquisition team to 55 territory managers by mid-2025 [20] - Focus on optimizing algorithm performance and user experience while expanding indications beyond seizure management [22] - The company aims to make EEG a new vital sign, targeting various neurological conditions [24][28] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving cash flow breakeven with the current cash on hand and the strength of the balance sheet [41] - The company anticipates full-year 2025 total revenue to be in the range of $81 million to $85 million, representing annual growth of 24% to 30% over 2024 [37] - Management highlighted the importance of maintaining a strong margin profile despite increased operating expenses due to public company status [34][41] Other Important Information - The company has made significant strides in commercial growth and R&D pipeline development, impacting tens of thousands of patients [7][9] - The company has received breakthrough device designation from the FDA for its delirium detection algorithm [25] Q&A Session Summary Question: Guidance for 2025 and underlying assumptions - Management indicated that guidance reflects continued investment in sales infrastructure, expecting growth to be consistent with 2024 [46] Question: Strength of new account adds in Q4 - Management noted that the strength of account adds was due to good planning and early launches [50] Question: Thoughts on gross margin and OpEx spend in 2025 - Management expects gross margins to normalize in the mid to high 80% range and anticipates a significant increase in R&D expenses [54][56] Question: Update on stroke detection algorithm - Management reported encouraging results from the stroke study and plans to expand enrollment speed for data collection [70] Question: Utilization of headbands per account - Management expects an upward trajectory in usage, although purchasing patterns may vary [90] Question: Update on VA facilities - Management expressed optimism regarding interest from VA hospitals and hopes to share tangible milestones in the next quarter [97]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-42364 CeriBell, Inc. (Exact name of Registrant as specified in its Charter) Delaware 47-1785452 (State or other jurisdiction of (I.R. ...

Ceribell Reports Fourth Quarter and Full Year 2024 Financial Results Sunnyvale, Calif. – February 25, 2025 – CeriBell, Inc. (Nasdaq: CBLL) ("Ceribell"), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 & Recent Highlights "2024 was a transformative year for Ceribell, as we advanced our mission to become the stand ...

Core Insights - Ceribell, Inc. reported a transformative year in 2024, focusing on becoming the standard of care for seizure management and executing key strategic initiatives, including an initial public offering [3] - The company aims to improve clinical outcomes for neurology patients and expand its indications to address unmet needs [3] Fourth Quarter 2024 Financial Results - Total revenue for Q4 2024 was $18.5 million, a 41% increase from $13.1 million in Q4 2023, driven by new account adoption and expansion within existing accounts [4] - Product revenue in Q4 2024 was $14.1 million, up 41% from $10.0 million in Q4 2023, while subscription revenue reached $4.4 million, a 40% increase from $3.1 million in Q4 2023 [4] - Gross profit for Q4 2024 was $16.2 million, with a gross margin of 88%, compared to $11.1 million and 85% in Q4 2023 [5] Operating Expenses and Net Loss - Operating expenses in Q4 2024 were $29.1 million, a 49% increase from $19.5 million in Q4 2023, primarily due to investments in the commercial organization and increased headcount [6] - The net loss for Q4 2024 was $12.6 million, or $0.40 per share, compared to a net loss of $8.3 million, or $1.53 per share, in Q4 2023 [7] Full Year 2024 Financial Results - Total revenue for the full year 2024 was $65.4 million, a 45% increase from $45.2 million in 2023, with product revenue at $50.1 million and subscription revenue at $15.4 million [8] - Gross profit for the full year 2024 was $56.8 million, with a gross margin of 87%, compared to $38.2 million and 84% in 2023 [9] - Operating expenses for the full year 2024 were $96.5 million, a 41% increase from $68.2 million in 2023, leading to a net loss of $40.5 million, or $3.39 per share [10] Cash Position - As of December 31, 2024, Ceribell had cash and cash equivalents totaling $194.4 million, a significant increase from $34.5 million at the end of 2023 [10] 2025 Financial Outlook - Ceribell expects revenue for the full year 2025 to be in the range of $81 million to $85 million, representing growth of approximately 24% to 30% over the previous year [11]

With a robust academic background including an MBA in Finance from NYU-Stern, and an MD from Delhi University, my journey in the financial world has been diverse and enriching. My postgraduate training in medicine was conducted at Harvard and Cornell affiliated hospitals, thus laying a solid foundation for my current expertise.As a registered investment advisor and professional money manager, I bring nearly a decade of experience in writing about income investing and biotech/pharma investing. My role at Vas ...

Core Insights - CeriBell, Inc. is participating in the 45th Annual TD Cowen Health Care Conference on March 3, 2025, with CEO Jane Chao and CFO Scott Blumberg featured in a fireside chat [1][2] Company Overview - CeriBell is a medical technology company focused on improving the diagnosis and management of serious neurological conditions [3] - The company has developed the Ceribell System, a point-of-care electroencephalography (EEG) platform designed for acute care settings [3] - The Ceribell System combines portable hardware with AI-powered algorithms for rapid diagnosis and continuous monitoring of neurological conditions [3] - The system is FDA 510(k) cleared for indicating suspected seizure activity and is currently used in intensive care units and emergency rooms across the U.S. [3]

SUNNYVALE, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that it will release financial results for the fourth quarter and full year of 2024 after the close of trading on Tuesday, February 25, 2025. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET on Febru ...

Company Overview - Ceribell, Inc. is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions [3] - The company has developed the Ceribell System, a novel point-of-care electroencephalography (EEG) platform designed for acute care settings [2][3] - The Ceribell System combines portable hardware with AI-powered algorithms for rapid diagnosis and continuous monitoring of neurological conditions [2] Product Details - The Ceribell System is FDA 510(k) cleared for indicating suspected seizure activity [2] - It is currently utilized in intensive care units and emergency rooms across the U.S. [2] Upcoming Events - Jane Chao, Ph.D., CEO and Co-founder of Ceribell, will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025, at 7:30 a.m. PST [3]

Group 1 - A strategy to identify quality under-the-radar stocks involves analyzing recent initial public offerings (IPOs) [1] - Promising growth outlooks in IPOs can lead to significant value creation for early investors [1] Group 2 - The article emphasizes the importance of early entry into promising IPOs for potential investment opportunities [1]